Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

Abstract Background In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastatic hormone sensitive prostate cancer (oHSPC). Howev...

Full description

Bibliographic Details
Main Authors: Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Format: Article
Language:English
Published: BMC 2020-09-01
Series:BMC Cancer
Subjects:
Hormone sensitive prostate Cancer
Lutetium-177-PSMA
Metastases directed therapy
Oligometastases
Radioligand therapy
Urologic oncology
Online Access:http://link.springer.com/article/10.1186/s12885-020-07386-z

Internet

http://link.springer.com/article/10.1186/s12885-020-07386-z

Similar Items